<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31268" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Von Hippel-Lindau Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mikhail</surname>
            <given-names>Magui I.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Achint K.</given-names>
          </name>
          <aff>Un of Texas Health Sci Ctr San Antonio</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Magui Mikhail declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Achint Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31268.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Von Hippel-Lindau (VHL) syndrome is an autosomal dominant disease affecting several organ systems. The growth of cysts or tumors characterizes the disease. Tumors can either be benign or malignant. The characteristic tumor type in VHL is hemangioblastoma, a benign tumor comprised of newly formed blood vessels. Hemangioblastomas in the central nervous system and retina can cause complications, including ataxia and vision loss. Renal cell carcinoma (RCC) and pancreatic neuroendocrine tumors are also seen in patients with VHL. This activity reviews the evaluation and management of&#x000a0;VHL syndrome and underscores the interprofessional team's role in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Assess the typical presentation of a patient with Von Hippel-Lindau syndrome.</p></list-item><list-item><p>Evaluate&#x000a0;the pathophysiology of Von Hippel-Lindau syndrome.</p></list-item><list-item><p>Interpret&#x000a0;the typical imaging findings associated with Von-Hippel Lindau lesions.</p></list-item><list-item><p>Communicate&#x000a0;the importance of improving care coordination amongst the interprofessional team to enhance the management and delivery of care for patients with Von Hippel-Lindau syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31268&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31268">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31268.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Von Hippel-Lindau (VHL) syndrome is a hereditary autosomal dominant disease affecting several organ systems. The growth of cysts or tumors characterizes the disease. Tumors can either be benign or malignant. The most characteristic type of tumor in VHL is hemangioblastoma, a benign tumor made of newly formed blood vessels. Hemangioblastomas develop in the central nervous system (CNS) and retina and can cause complications, including ataxia and vision loss. Cysts are a common manifestation of VHL in the kidneys, pancreas, and genital tract. Renal cell carcinoma (RCC) and pancreatic neuroendocrine tumors are also seen with VHL.&#x000a0;Endolymphatic sac tumors found in the inner ear can be seen in patients with VHL.<xref ref-type="bibr" rid="article-31268.r1">[1]</xref><xref ref-type="bibr" rid="article-31268.r2">[2]</xref><xref ref-type="bibr" rid="article-31268.r3">[3]</xref><xref ref-type="bibr" rid="article-31268.r4">[4]</xref>&#x000a0;Close to 50% of patients with VHL have hemangiomas, which can occur in any part of the retina. These hemangiomas may leak serum, forming microglial bands&#x000a0;that can cause retinal detachment and vitreous hemorrhage. The result is the development of glaucoma or permanent vision loss.</p>
        <p>VHL can be classified as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Type 1 (without pheochromocytoma)</p>
          </list-item>
          <list-item>
            <p>Type 2 (with pheochromocytoma).
<list list-type="bullet"><list-item><p>Type 2 is further classified as:
<list list-type="bullet"><list-item><p>Type 2A: Pheochromocytoma is present along with CNS hemangioblastomas but no RCC.</p></list-item><list-item><p>Type 2B: Pheochromocytoma CNS hemangioblastomas and RCC are present.</p></list-item><list-item><p>Type 2C: Pheochromocytoma is present without hemangioblastomas&#x000a0;or RCC.</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31268.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Mutations in the <italic toggle="yes">VHL</italic> tumor suppressor gene located on chromosome 3 cause&#x000a0;VHL. These mutations prevent the production or cause abnormal VHL protein (pVHL) production. pVHL is primarily responsible for the degradation of hypoxia-inducible factor (HIF), a protein&#x000a0;responsible for cell oxygen regulation. Abnormal or absent pVHL results in the uninhibited upregulation of HIF and multiple downstream&#x000a0;growth factors, leading to the formation of cysts and hypervascular tumors characteristic of VHL.</p>
      </sec>
      <sec id="article-31268.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>VHL is autosomal dominant and has a high penetrance, leading to early onset and high frequency of clinical manifestations. It is the most common hereditary renal cancer syndrome.&#x000a0;The estimated prevalence of VHL is 1&#x000a0;per 30,000 to 1&#x000a0;per 50,000, with 6000 to 7000 patients affected in the United States. Males and females are equally affected. The average age of onset is 26 years, with an age range of infancy to the seventh decade but most commonly at 18 to 30 years. Renal cysts occur in 59% to 63% of patients. RCC occurs in 25% to 45%. CNS hemangioblastomas occur in 13% to 72%. Retinal hemangioblastomas occur in 45% to 59%. Endolymphatic sac tumors occur in 2% to 11%. Pancreatic lesions occur in 17% to 56%, and pheochromocytomas occur in 0% to 60%.<xref ref-type="bibr" rid="article-31268.r5">[5]</xref></p>
      </sec>
      <sec id="article-31268.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>VHL is caused by an autosomal dominant mutation of the von Hippel&#x02013;Lindau tumor suppressor gene on chromosome 3, resulting in an abnormal pVHL. pVHL regulates a protein known as HIF-1-alpha, which is responsible for cellular response to hypoxia. VHL genetic mutations result&#x000a0;in alterations to pVHL at the&#x000a0;HIF-1-alpha binding site. As a result, pVHL does not bind effectively to HIF-1-alpha, which, in turn, leads to the transcription of several genes and subsequent upregulation of growth factors, including erythropoietin, vascular endothelial growth factor, platelet-derived growth factor B, and other genes involved in glucose uptake and metabolism.</p>
      </sec>
      <sec id="article-31268.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Presenting history varies in patients depending on the size and location of tumors. Family history is important, given the hereditary nature of&#x000a0;VHL.&#x000a0;Hemangioblastomas in the CNS can cause headaches, vomiting, sensory or motor deficits, and ataxia. Hemangioblastomas in the retina, also known as retinal angiomas, may cause vision loss. Pheochromocytomas, which affect the adrenal glands, may be asymptomatic, but they may also cause an array of symptoms, including headaches, panic attacks, excessive sweating, and elevated blood pressure. VHL patients with endolymphatic sac tumors in the inner ear may present with tinnitus, vertigo, or hearing loss.</p>
        <p>Physical examination findings are usually limited since the diagnosis is generally based on laboratory and radiographic studies. However, in the case of CNS hemangioblastomas, physical examination may yield positive neurological findings such as muscle weakness, sensory deficits, and ataxia.</p>
      </sec>
      <sec id="article-31268.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Identification of a heterozygous pathogenic variant of pVHL using molecular genetic testing&#x000a0;establishes the diagnosis of VHL even if clinical and radiographic findings are inconclusive. Various&#x000a0;clinical criteria can establish the diagnosis, such as more than&#x000a0;1 CNS hemangioblastoma,&#x000a0;1 CNS hemangioblastoma, a visceral manifestation of VHL, or any manifestation with a family history of VHL.<xref ref-type="bibr" rid="article-31268.r5">[5]</xref><xref ref-type="bibr" rid="article-31268.r6">[6]</xref><xref ref-type="bibr" rid="article-31268.r7">[7]</xref><xref ref-type="bibr" rid="article-31268.r8">[8]</xref>&#x000a0;Fundoscopy can detect retinal hemangioblastomas and other associated&#x000a0;findings such as retinal detachment, macular edema, or cataracts. Glaucoma may be detectable on tonometry. An audiological evaluation should be done to evaluate for hearing loss caused by endolymphatic sac tumors. Laboratory studies include serum and urinary catecholamines that can assist in diagnosing pheochromocytomas.</p>
        <p>Imaging studies play a significant role in identifying VHL lesions. CNS hemangioblastomas are detectable on MR of the brain and spinal cord. Their typical appearance is a cystic lesion with an enhancing mural nodule.<xref ref-type="bibr" rid="article-31268.r9">[9]</xref> About 80% develop in the brain and 20% in the spinal cord. Renal cysts can be detected on ultrasound, MRI, or CT and are usually bilateral, multiple, and of different sizes. CT with the renal mass protocol is the preferred imaging tool for RCC, which generally occurs bilaterally and can appear as multiple lesions and solid or cystic. CT or MR can identify pheochromocytomas. Usually, pancreatic cysts and tumors are&#x000a0;detected on CT. Pancreatic cysts can also be visualized on ultrasound. MR and CT through the middle ear can detect endolymphatic sac tumors.</p>
      </sec>
      <sec id="article-31268.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of VHL syndrome depends on the lesions' location and size and the disease's extent. CNS hemangioblastomas can be excised&#x000a0;surgically. Gamma-knife surgery may be useful for small solid tumors or ones in inoperable sites.&#x000a0;If hemangioblastomas are extensive, preoperative embolization is performed to decrease bleeding&#x000a0;risk, given the high vascularity of these tumors. Retinal angiomas are usually treated to avoid vision loss. Treatment options include diathermy, xenon, laser, cryocoagulation, and external beam radiotherapy. Early nephrectomy is the best treatment option for RCC. Smaller lesions are also treated with cryoablation and radiofrequency ablation. Pheochromocytomas are removed&#x000a0;surgically. Partial adrenalectomy is the treatment of choice for pediatric patients. Surgical removal of&#x000a0;pancreatic neuroendocrine tumors should be considered if they pose a high risk of metastasis, as suggested by a tumor size greater than 3 cm, a doubling rate of fewer than 500 days, or a pathologic genetic variant. Surgical removal of endolymphatic sac tumors should be considered to avoid hearing loss.<xref ref-type="bibr" rid="article-31268.r10">[10]</xref><xref ref-type="bibr" rid="article-31268.r11">[11]</xref></p>
      </sec>
      <sec id="article-31268.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of VHL contains all types of VHL-associated tumors as isolated entities, including retinal hemangioblastoma, renal cell carcinoma, CNS hemangioblastoma, pheochromocytoma, pancreatic tumors, and endolymphatic sac tumors.</p>
      </sec>
      <sec id="article-31268.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Because many patients with VHL develop renal cell cancer, their life expectancy is reduced. The morbidity depends on the number of organs involved. The presence of CNS hemangioblastomas also affects morbidity. The lesions often expand and lead to neurological compromise. Retinal disease can be associated with cataracts, glaucoma, retinal detachment, macular exudation, and vitreous hemorrhage. The endolymphatic sac tumors are often bilateral and induce tinnitus, hearing loss, and facial weakness. Patients with VHL are also at risk of developing pheochromocytomas. The pancreatic cystic lesions rarely cause symptoms and do not become malignant. Overall, the quality of life of these patients is poor.</p>
      </sec>
      <sec id="article-31268.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Without treatment, VHL&#x000a0;patients may have blindness or permanent brain damage. Death usually&#x000a0;results from the complications of brain tumors or kidney cancer.</p>
      </sec>
      <sec id="article-31268.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Since treatment usually involves surgery or radiation therapy, patients and their families need to understand the risks and benefits of those interventions. The condition also requires ongoing monitoring, so patient compliance is crucial. Genetic counseling should also be pursued.</p>
      </sec>
      <sec id="article-31268.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Early detection of VHL syndrome through surveillance and screening can help minimize complications, including neurological deficits, hearing and vision loss, and renal impairment. For individuals with known VHL syndrome, a known VHL genetic mutation, or first-degree relatives of VHL patients, annual evaluation starting at age&#x000a0;1 for vision and hearing problems, neurological symptoms, and blood pressure monitoring is recommended. An MRI of the brain and entire spine is recommended every 2 years starting at age 16 to screen for CNS lesions. An abdominal ultrasound or MRI is recommended for visceral lesions starting at age 16 every 1 to 2 years. Annual blood or urinary fractionated metanephrines&#x000a0;are used to screen for pheochromocytomas starting at age 5. For endolymphatic sac tumors, an MRI with thin slices through the internal auditory canal is recommended in symptomatic patients. An audiology evaluation every 2 to 3 years starting at age&#x000a0;5 can help detect early hearing deficits. Genetic counseling and testing should be offered to individuals at risk to&#x000a0;assist in diagnostic confirmation&#x000a0;and prevent screening tests in individuals without the pathogenic variant.</p>
      </sec>
      <sec id="article-31268.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An interprofessional healthcare team optimally manages patients with VHL. This team involves clinicians (including NPs and PAs), specialists, oncology-specialty nurses, and pharmacists, all collaborating and communicating to drive the best possible patient outcomes. These patients need lifelong monitoring. Family members need surveillance and screening, which can help minimize complications, including neurological deficits, hearing and vision loss, and renal impairment. For individuals with known VHL syndrome, a known VHL genetic mutation, or first-degree relatives of VHL patients, annual evaluation starting at age&#x000a0;1 for vision and hearing problems, neurological symptoms, and blood pressure monitoring is recommended. An MRI of the brain and entire spine is recommended every 2 years starting at age 16 to screen for CNS lesions. An abdominal ultrasound or MRI is recommended for visceral lesions starting at age 16 every 1 to 2 years. Annual blood or urinary fractionated metanephrines&#x000a0;are used to screen for pheochromocytomas starting at age 5. For endolymphatic sac tumors, an MRI is recommended in symptomatic patients. An audiology evaluation every 2 to 3 years, starting at age 5, can help detect early hearing deficits.&#x000a0;Genetic counseling and testing should be offered to individuals at risk to confirm the diagnosis and prevent screening tests in individuals without the pathogenic variant. The prognosis for most patients with VHL is guarded, and the quality of life for these patients is not good.</p>
      </sec>
      <sec id="article-31268.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31268&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31268">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/von-hippel-lindau-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=31268">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31268/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31268">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-31268.s16">
        <title>References</title>
        <ref id="article-31268.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chappell</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Rathmell</surname>
                <given-names>WK</given-names>
              </name>
            </person-group>
            <article-title>Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers.</article-title>
            <source>J Clin Invest</source>
            <year>2019</year>
            <month>Feb</month>
            <day>01</day>
            <volume>129</volume>
            <issue>2</issue>
            <fpage>442</fpage>
            <page-range>442-451</page-range>
            <pub-id pub-id-type="pmid">30614813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31268.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yi</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Clinical Syndromes and Genetic Screening Strategies of Pheochromocytoma and Paraganglioma.</article-title>
            <source>J Kidney Cancer VHL</source>
            <year>2018</year>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>14</fpage>
            <page-range>14-22</page-range>
            <pub-id pub-id-type="pmid">30613466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31268.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsang</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Von Hippel-Lindau Disease.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2018</year>
            <volume>1085</volume>
            <fpage>201</fpage>
            <page-range>201-203</page-range>
            <pub-id pub-id-type="pmid">30578515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31268.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barros</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Marussi</surname>
                <given-names>VHR</given-names>
              </name>
              <name>
                <surname>Amaral</surname>
                <given-names>LLF</given-names>
              </name>
              <name>
                <surname>da Rocha</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Campos</surname>
                <given-names>CMS</given-names>
              </name>
              <name>
                <surname>Freitas</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Huisman</surname>
                <given-names>TAGM</given-names>
              </name>
              <name>
                <surname>Soares</surname>
                <given-names>BP</given-names>
              </name>
            </person-group>
            <article-title>The Rare Neurocutaneous Disorders: Update on Clinical, Molecular, and Neuroimaging Features.</article-title>
            <source>Top Magn Reson Imaging</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>433</fpage>
            <page-range>433-462</page-range>
            <pub-id pub-id-type="pmid">30516694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31268.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>van Leeuwaarde</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van Nesselrooij</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zandee</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Giles</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <chapter-title>Von Hippel-Lindau Syndrome</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2000</year>
            <month>5</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">20301636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31268.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Signoretti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Flaifel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Reuter</surname>
                <given-names>VE</given-names>
              </name>
            </person-group>
            <article-title>Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers.</article-title>
            <source>J Clin Oncol</source>
            <year>2018</year>
            <month>Oct</month>
            <day>29</day>
            <volume>36</volume>
            <issue>36</issue>
            <fpage>JCO2018792259</fpage>
            <pub-id pub-id-type="pmid">30372384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31268.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koch</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Petersenn</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Black swans - neuroendocrine tumors of rare locations.</article-title>
            <source>Rev Endocr Metab Disord</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>111</fpage>
            <page-range>111-121</page-range>
            <pub-id pub-id-type="pmid">30341705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31268.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yilmaz</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>[CNS manifestations of neurocutaneous syndromes].</article-title>
            <source>Radiologe</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>58</volume>
            <issue>7</issue>
            <fpage>664</fpage>
            <page-range>664-667</page-range>
            <pub-id pub-id-type="pmid">29947935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31268.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Das</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kesavapisharady</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sadasivam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>Microsurgical Treatment of Sporadic and von Hippel-Lindau Disease Associated Spinal Hemangioblastomas: A Single-Institution Experience.</article-title>
            <source>Asian Spine J</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>548</fpage>
            <page-range>548-555</page-range>
            <pub-id pub-id-type="pmid">28874972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31268.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ganeshan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Menias</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Pickhardt</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Sandrasegaran</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lubner</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Ramalingam</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bhalla</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Tumors in von Hippel-Lindau Syndrome: From Head to Toe-Comprehensive State-of-the-Art Review.</article-title>
            <source>Radiographics</source>
            <year>2018</year>
            <season>May-Jun</season>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>982</fpage>
            <pub-id pub-id-type="pmid">29757728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31268.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maher</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management.</article-title>
            <source>World J Urol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>36</volume>
            <issue>12</issue>
            <fpage>1891</fpage>
            <page-range>1891-1898</page-range>
            <pub-id pub-id-type="pmid">29680948</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
